The nation of Zimbabwe has turned down a significant US health deal worth 367 million US dollars (272 million pounds) spanning five years over the United States' demand for confidential biological samples.
This rejection became public after a internal memorandum from December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the agreement was "lopsided".
A government spokesman later clarified that the US was requesting genetic material for research and profit while refused to share the resulting advantages from any future treatments.
"We must now begin the difficult and regrettable process of ending our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had donated more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged more negotiations to reach a agreement agreeable to both sides so the country's critical HIV treatment initiative can proceed.
Wider Context
This development follows a similar case in Kenya, where a high court suspended a related health funding agreement following concerns were raised about the safety of citizens' health data.
After returning to the presidency last year, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
The agency had overseen assistance for the American government, but Trump argued its spending was "inefficient" and his government was pursuing direct bilateral agreements to enhance transparency and responsibility.
According to statements, Sixteen African countries have to date agreed to these new agreements, representing more than $18.3bn of fresh investment.
Specifics of the Declined Agreement
This assistance for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership could have provided significant benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently receiving HIV treatment via US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana maintained the proposed deal was "asymmetrical".
"Our nation was requested to provide its biological resources and data for a long time, with no equivalent guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that might be developed from that shared data," Mangwana explained.
"In essence, our country would supply the raw materials for scientific discovery with no certainty that the resulting innovations would be accessible to our population if a future pandemic emerge."
Sovereignty and International Frameworks
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were undermining frameworks previously set up through the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to manage future global health emergencies.
"This mechanism is designed to ensure that when a nation contributes its samples, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the funds to develop them."
The government's concerns over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome further dialogue with our American counterparts on how subsequent collaboration could be designed in a manner that respects the independence and interests of each country."
Medical Community Reaction
A leading public health body said it understood the government's concerns, but urged that negotiations should continue given that a large portion of the nation's Aids initiatives were funded by international support.
"Where technical issues arise, including those involving data governance or agreement terms, these can often be resolved via technical clarification and mutually agreed protections," the group said.
The situation underscores the complex debate between receiving vital foreign assistance and safeguarding national sovereignty in an ever more interconnected world.